Related Experiment Videos
Immunosuppressive activity of bromocriptine on human T lymphocyte function in vitro
K Morikawa1, F Oseko, S Morikawa
1Department of Internal Medicine, Shimane Medical University, Japan.
Clinical and Experimental Immunology
|March 1, 1994
Summary
Bromocriptine (BRC) suppresses T cell proliferation by blocking Interleukin-2 (IL-2) production, independent of its prolactin-lowering effects. Combining BRC with immunosuppressants like cyclosporin A enhances T cell suppression.
Area of Science:
- Immunology
- Pharmacology
Background:
- Bromocriptine (BRC), a dopamine agonist, reduces prolactin (PRL) secretion, impacting immune responses.
- Previous studies suggested BRC's immunosuppression stems from lowered PRL levels, a mechanism not fully elucidated.
- The direct impact of BRC on T cell function required further investigation.
Purpose of the Study:
- To investigate the direct mechanism of Bromocriptine (BRC) on human T cell function.
- To determine if BRC's immunosuppressive activity is linked to its prolactin-lowering effect.
- To explore the synergistic effects of BRC with other immunosuppressants.
Main Methods:
- Assessing T cell proliferation and Interleukin-2 (IL-2) production in response to BRC in vitro.
- Evaluating mixed lymphocyte reactions (MLR) under BRC treatment.
- Analyzing the effects of combining BRC with cyclosporin A (CsA) or FK506 on T cell responses.
Main Results:
- BRC demonstrated dose-dependent suppression of T cell proliferation and blocked IL-2 production.
- No immunoreactive PRL was detected in T cell cultures, indicating BRC's effect is independent of PRL.
- Combined treatment with BRC and CsA or FK506 showed enhanced suppression of T cell proliferation and CD25 expression.
Conclusions:
- BRC directly suppresses human T cell function by inhibiting IL-2 production, independent of its hypoprolactinaemic effect.
- The combination of BRC with standard immunosuppressants may offer a more effective therapeutic strategy with potentially reduced toxicity.